reports
Corbus Pharmaceuticals to Present CRB-701 Phase 1/2 Data at ESMO 2025
Corbus Pharmaceuticals to Present CRB-701 Phase 1/2 Data at ESMO 2025 Data to be presented for 167 enrolled participants of which 122 were evaluable for efficacy Company to host HNSCC KOL event to review and discuss data NORWOOD, Mass., Oct. 14, 2025 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings Inc. (NASDAQ: CRBP), a clinical stage company focused on oncology and obesity, announced today the European Society for Medical Oncology (ESMO) Congress 2025 for its Phase 1/2 clinical study has been released. Updated data will be presented as a poster duri...
- Wedbush Research
RARE ULTRAGENYX PHARMACEUTICAL INC.
QLYS QUALYS INC.
PANW PALO ALTO NETWORKS INC.
NVCR NOVOCURE LTD.
NBIX NEUROCRINE BIOSCIENCES INC.
KURA KURA ONCOLOGY INC.
FTNT FORTINET INC.
CYBR CYBERARK SOFTWARE LTD.
CHKP CHECK POINT SOFTWARE TECHNOLOGIES LTD.
BIIB BIOGEN INC.
BCRX BIOCRYST PHARMACEUTICALS INC.
ARDX ARDELYX INC
ISR ISORAY
APLS APELLIS PHARMACEUTICALS
DNLI DENALI THERAPEUTICS INC
RCUS ARCUS BIOSCIENCES
ZS ZSCALER INC.
TENB TENABLE HOLDINGS
ARVN ARVINAS HOLDING
CRWD CROWDSTRIKE HOLDINGS INC. CLASS A
DDOG DATADOG INC CLASS A
APRE APREA THERAPEUTICS
IDYA IDEAYA BIOSCIENCES
RVMD REVOLUTION MEDICINES
ORIC ORIC PHARMACEUTICALS
ZNTL ZENTALIS PHARMACEUTICALS
TVTX TRAVERE THERAPEUTICS INC
IMNM IMMUNOME
NUVB NUVATION BIO INC (A)
CGEM CULLINAN ONCOLOGY INC
DAWN DAY ONE BIOPHARMACEUTICALS INC
FHTX FOGHORN THERAPEUTICS
TNGX TANGO THERAPEUTICS
TCRX INC
GLUE TSCAN THERAPEUTICS INC
S MONTE ROSA THERAPEUTICS INC
TYRA SENTINELONE INC
NUVL TYRA BIOSCIENCES INC
CRBP NUVALENT INC
RBRK CORBUS PHARMACEUTICALS HOLDINGS INC.
BCAX RUBRIK INC
BBOT BICARA THERAPEUTICS INC.
BRIDGEBIO ONCOLOGY THERAPEUTICS INC
- David Nierengarten
- Dennis Pak
- Geoffrey Von Der Ahe
- Martin Fan
- Ritika Das
- Robert Driscoll
ISR ISORAY
RCUS ARCUS BIOSCIENCES
ARVN ARVINAS HOLDING
IDYA IDEAYA BIOSCIENCES
RVMD REVOLUTION MEDICINES
ORIC ORIC PHARMACEUTICALS
IMNM IMMUNOME
NUVB NUVATION BIO INC (A)
CGEM CULLINAN ONCOLOGY INC
DAWN DAY ONE BIOPHARMACEUTICALS INC
TCRX TSCAN THERAPEUTICS INC
TYRA TYRA BIOSCIENCES INC
NUVL NUVALENT INC
CRBP CORBUS PHARMACEUTICALS HOLDINGS INC.
BCAX BICARA THERAPEUTICS INC.
BBOT BRIDGEBIO ONCOLOGY THERAPEUTICS INC
- Wedbush Research
TPH TRI POINTE HOMES INC.
TOL TOLL BROTHERS INC.
NVCR NOVOCURE LTD.
KURA KURA ONCOLOGY INC.
ACRS ACLARIS THERAPEUTICS INC.
FRX_CN FENNEC PHARMACEUTICALS
TMHC TAYLOR MORRISON HOME CORPORATION
WVE WAVE LIFE SCIENCES
MHO M/I HOMES INC.
ANAB ANAPTYSBIO INC.
ARGX ARGENX ADS
RCUS ARCUS BIOSCIENCES
KNSA KINIKSA PHARMACEUTICALS
IDYA IDEAYA BIOSCIENCES
BEAM BEAM THERAPEUTICS
NUVB NUVATION BIO INC (A)
CGEM CULLINAN ONCOLOGY INC
NUVL NUVALENT INC
PRME PRIME MEDICINE INC
CRBP CORBUS PHARMACEUTICALS HOLDINGS INC.
STUB STUBHUB HOLDINGS INC.
- David Nierengarten
- Dennis Pak
- Geoffrey Von Der Ahe
- Laura Chico
- Martin Fan
- Ritika Das
- Robert Driscoll
- Yun Zhong
ACRS ACLARIS THERAPEUTICS INC.
WVE WAVE LIFE SCIENCES
ANAB ANAPTYSBIO INC.
RCUS ARCUS BIOSCIENCES
IDYA IDEAYA BIOSCIENCES
BEAM BEAM THERAPEUTICS
NUVB NUVATION BIO INC (A)
CGEM CULLINAN ONCOLOGY INC
NUVL NUVALENT INC
PRME PRIME MEDICINE INC
CRBP CORBUS PHARMACEUTICALS HOLDINGS INC.
Corbus Pharmaceuticals to Participate in the Upcoming Piper Sandler Vi...
Corbus Pharmaceuticals to Participate in the Upcoming Piper Sandler Virtual Oncology Symposium NORWOOD, Mass., Oct. 07, 2025 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), a clinical stage oncology and obesity company, today announced that Yuval Cohen, Ph.D., Chief Executive Officer of Corbus, will participate in a Fireside Chat at the Piper Sandler Virtual Oncology Symposium, to be held October 9-10, 2025. Piper Sandler clients can register for the event through their representative. Corbus Fireside ChatOctober 9, 2025, 10:00AM ETHo...
FreightCar America, Inc. to Attend Noble Virtual Equity Conference
FreightCar America, Inc. to Attend Noble Virtual Equity Conference CHICAGO, Oct. 01, 2025 (GLOBE NEWSWIRE) -- FreightCar America, Inc. (NASDAQ: RAIL) (“FreightCar America” or the “Company”), a diversified manufacturer and supplier of railroad freight cars, railcar parts and components, today announced that Nick Randall, Chief Executive Officer, and Michael Riordan, Chief Financial Officer, will participate in one-on-one meetings with investors at the Noble Emerging Growth Virtual Equity Conference, taking place on October 8, 2025. For additional information or to request a meeting, pleas...
FDA Grants Fast Track Designation to Corbus Pharmaceuticals’ Nectin-4 ...
FDA Grants Fast Track Designation to Corbus Pharmaceuticals’ Nectin-4 Targeting ADC CRB-701 in Head and Neck Squamous Cell Carcinoma Dose optimization data from the Phase 1/2 study to be presented next month at ESMO 2025Second Fast Track designation granted by FDA for CRB-701 NORWOOD, Mass., Sept. 16, 2025 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), a clinical stage oncology and obesity company, announced today that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to CRB-701 for the treatment of recur...
FreightCar America, Inc. to Present at Midwest IDEAS Conference
FreightCar America, Inc. to Present at Midwest IDEAS Conference CHICAGO, Aug. 20, 2025 (GLOBE NEWSWIRE) -- FreightCar America, Inc. (NASDAQ: RAIL) (“FreightCar America” or the “Company”), a diversified manufacturer and supplier of railroad freight cars, railcar parts and components, today announced that senior management will present and host one-on-one meetings with investors at the Midwest IDEAS Conference, taking place on August 26-27, 2025 in Chicago. Michael Riordan, Chief Financial Officer, will begin the presentation at 4:50 PM CT on August 27th, and will also host one-on-ones wit...
- Geoffrey Von Der Ahe
- Ritika Das
- Robert Driscoll
Corbus Pharmaceuticals Reports Second Quarter 2025 Financial Results a...
Corbus Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides a Corporate Update Phase 1/2 dose expansion data for Nectin-4 targeting ADC CRB-701 to be presented at ESMO 2025Initiated 7-day MAD portion of Phase 1 study for obesity drug CRB-913All three clinical programs (CRB-701, CRB-913, CRB-601) on track for data readouts in the second half of 2025 NORWOOD, Mass., Aug. 05, 2025 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), a clinical stage oncology and obesity company, today provided a corporate update and repo...
FreightCar America, Inc. Reports Second Quarter 2025 Results
FreightCar America, Inc. Reports Second Quarter 2025 Results Delivered Gross Margin of 15%, Expansion of 250 Basis PointsOperating Cash Flow of $8.5 Million and Adjusted Free Cash Flow of $7.9 MillionStrong Order Intake Driven by Operational Flexibility, Reaffirmed Full Year Guidance CHICAGO, Aug. 04, 2025 (GLOBE NEWSWIRE) -- FreightCar America, Inc. (NASDAQ: RAIL) (“FreightCar America” or the “Company”), a diversified manufacturer and supplier of railroad freight cars, railcar parts and components, today reported results for the second quarter ended June 30, 2025. Second Quarter 2025 H...
Corbus Pharmaceuticals Announces Upcoming Presentation of Dose Expansi...
Corbus Pharmaceuticals Announces Upcoming Presentation of Dose Expansion Phase 1/2 Clinical Data for its Nectin-4 Targeting ADC CRB-701 at the 2025 ESMO Annual Congress NORWOOD, Mass., July 30, 2025 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings Inc. (NASDAQ: CRBP), a clinical-stage company focused on oncology and obesity, announced today that an abstract on updated clinical data from its Phase 1/2 clinical study conducted in the United States and Europe of CRB-701 (SYS6002) has been accepted for presentation as a poster at the (ESMO) Congress 2025, to be held October 17-21, 2025 in...
FreightCar America, Inc. To Release Second Quarter 2025 Results On Aug...
FreightCar America, Inc. To Release Second Quarter 2025 Results On August 4, 2025 CHICAGO, July 21, 2025 (GLOBE NEWSWIRE) -- FreightCar America, Inc. (NASDAQ: RAIL), a diversified manufacturer of railroad freight cars, today announced that it will release its second quarter 2025 financial results on Monday, August 4, 2025, after the market close and host a teleconference to discuss its second quarter 2025 results on the following day. Teleconference details are as follows: August 5, 202511:00 a.m. Eastern Daylight TimePhone: 1-877-407-0789 or 1-201-689-8562Webcast access: Please no...
Corbus Pharmaceuticals Initiates Multiple Ascending Dose Portion of Ph...
Corbus Pharmaceuticals Initiates Multiple Ascending Dose Portion of Phase 1 Study of Highly Peripherally Restricted CB1 Inverse Agonist CRB-913 for the Treatment of Obesity No treatment-related neuropsychiatric events seen to date in SAD portion of Phase 1MAD study on track for completion in Q3 2025 NORWOOD, Mass., June 30, 2025 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings Inc. (NASDAQ: CRBP), a clinical-stage company focused on oncology and obesity, today announced the initiation of the multiple ascending dose (MAD) portion of its Phase 1 trial for CRB-913, a highly peripherally ...
Corbus Pharmaceuticals Announces First Patient Dosed with its Nectin-4...
Corbus Pharmaceuticals Announces First Patient Dosed with its Nectin-4 Targeting ADC CRB-701 in Combination with Pembrolizumab Combination cohort initiated following successful review of monotherapy cohortOver 100 participants dosed to-date in monotherapy cohortPriority are Head and Neck Squamous Cell Carcinoma (HNSCC) and cervical cancerData update on schedule for later this year NORWOOD, Mass., June 25, 2025 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), a clinical-stage company focused on oncology and obesity, today announced th...
Corbus Pharmaceuticals to Participate in the 3rd Annual Piper Obesity ...
Corbus Pharmaceuticals to Participate in the 3rd Annual Piper Obesity Symposium NORWOOD, Mass., June 24, 2025 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), today announced that Yuval Cohen, Ph.D., Chief Executive Officer of Corbus, will participate in a fire side chat at the Piper Sandler 3rd Annual Virtual Obesity Symposium, to be held on June 26, 2025. The event will include presentations by key opinion leaders and fireside chats with companies developing obesity therapeutics. Piper Sandler clients can register for the event throug...
- Wedbush Research
PEGA PEGASYSTEMS INC.
KURA KURA ONCOLOGY INC.
ISR ISORAY
CRWD CROWDSTRIKE HOLDINGS INC. CLASS A
SWTX SPRINGWORKS THERAPEUTICS
IDYA IDEAYA BIOSCIENCES
ORIC ORIC PHARMACEUTICALS
SNOW SNOWFLAKE INC. CLASS A
TNGX TANGO THERAPEUTICS
GLUE INC
JANX MONTE ROSA THERAPEUTICS INC
MLTX JANUX THERAPEUTICS INC
CRBP MOONLAKE IMMUNOTHERAPEUTICS
BCAX CORBUS PHARMACEUTICALS HOLDINGS INC.
BICARA THERAPEUTICS INC.
- David Nierengarten
- Dennis Pak
- Martin Fan
- Ritika Das
- Robert Driscoll
FreightCar America, Inc. to Attend Noble Virtual Equity Conference
FreightCar America, Inc. to Attend Noble Virtual Equity Conference CHICAGO, May 28, 2025 (GLOBE NEWSWIRE) -- FreightCar America, Inc. (NASDAQ: RAIL or the “Company”), a diversified manufacturer and supplier of railroad freight cars, railcar parts and components, today announced that it will participate in the Noble Capital Markets Virtual Equity Conference on June 4, 2025. Nick Randall, President and Chief Executive Officer, and Mike Riordan, Chief Financial Officer, will host one-on-one meetings with investors throughout the day. For additional information or to request a meeting, plea...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.